Thermo Fisher Scientific
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Thermo Fisher Scientific's revenues will increase 0.4% and EPS will grow 8.5%.
The average estimate for revenue is $3.15 billion. On the bottom line, the average EPS estimate is $1.28.
Last quarter, Thermo Fisher Scientific booked revenue of $3.09 billion. GAAP reported sales were 5.2% higher than the prior-year quarter's $2.93 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.19. GAAP EPS of $0.80 for Q3 were 14% higher than the prior-year quarter's $0.70 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 42.2%, 20 basis points worse than the prior-year quarter. Operating margin was 12.6%, 10 basis points worse than the prior-year quarter. Net margin was 9.4%, 40 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $12.40 billion. The average EPS estimate is $4.85.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 552 members out of 573 rating the stock outperform, and 21 members rating it underperform. Among 183 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 181 give Thermo Fisher Scientific a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $64.21.
Looking for alternatives to Thermo Fisher Scientific? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Thermo Fisher Scientific to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. TMFDisclosureHere